US Government Simulation
S. 29119th Congress (2025-2026)

Affordable Insulin and Prescription Drug Competition Act

Sponsor:
Sen. Collins, Susan[R-ME](Introduced January 1, 2025)|
Latest Action:
United States Senate - 07/02/2025 Action taken: FLOOR DEBATE.
Roll Call Votes:
  • United States Senate - 02/05/2025 | COMMITTEE VOTE: Passed (8 Yea, 0 Nay)
Tracker:
✓
Introduced01/01/2025
2
Passed Senate
3
Passed House
4
To President
5
Became Law
119TH CONGRESS

S. 29

IN THE SENATE OF THE UNITED STATES
January 1, 2025
Sen. Collins of Maine introduced the following bill

A BILL

To cap monthly out-of-pocket insulin costs for patients with commercial health insurance, prohibit anti-competitive Pharmacy Benefit Manager practices, expedite Food and Drug Administration review of generic biosimilar insulin products, and for other purposes.

Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

This Act may be cited as the "Affordable Insulin and Prescription Drug Competition Act".

SECTION 2. LIMITATION ON COMMERCIAL INSULIN COST-SHARING.

a) No pharmaceutical manufacturer, wholesaler, or pharmacy shall charge a total wholesale or retail list price exceeding $20 per vial or $35 per thirty-day supply of prescription insulin for any patient in the United States, whether insured or uninsured.

b) Cost-sharing limitations under this section shall apply regardless of whether the enrollee has satisfied the plan's annual deductible.

c) PROTECTION FOR UNINSURED AND CASH-PAYING PATIENTS.—Any individual without health insurance coverage, or whose coverage is not applied at the point of sale, shall be entitled to purchase covered insulin products at any licensed pharmacy for no more than the $20 per vial or $35 per thirty-day supply ceiling established under subsection (a).

d) PROHIBITION ON PREMIUM SHIFTING AND CROSS-DRUG PRICE HIKES.—

  1) Health insurance issuers shall not increase annual plan premiums or deductibles to offset reduced insulin cost-sharing.

  2) Pharmaceutical manufacturers subject to this section shall be prohibited from increasing the wholesale acquisition cost of other life-saving prescription medications above the rate of medical inflation to compensate for reduced insulin revenues.

SECTION 3. PHARMACY BENEFIT MANAGER TRANSPARENCY AND FAIRNESS.

a) Pharmacy Benefit Managers (PBMs) shall not charge a health plan or patient a co-payment or reimbursement rate for prescription insulin that exceeds the net acquisition cost of the medication.

b) No Pharmacy Benefit Manager shall restrict, penalize, or steer patients away from independent community pharmacies toward affiliated mail-order or retail pharmacies.

SECTION 4. EXPEDITED FDA APPROVAL OF BIOSIMILAR INSULIN.

a) The Food and Drug Administration (FDA) shall establish a priority review pathway for generic and interchangeable biosimilar insulin applications, issuing final determinations within 180 days of submission.

b) Brand-name pharmaceutical manufacturers shall be prohibited from entering into pay-for-delay settlements that postpone the market entry of approved biosimilar competitors.

SECTION 5. EFFECTIVE DATE.

This Act shall take effect on January 1 of the first calendar year following the date of enactment.

S. 29: Affordable Insulin and Prescription Drug Competition Act | US Government Simulation